HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Heidi Goerler Axel Haverich Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goerler, H. Articles by Haverich, A. Search for Related Content PubMed PubMed Citation Articles by Goerler, H. Articles by Haverich, A. Related Collections Coronary disease

Eur J Cardiothorac Surg 2007;32:560-566. doi:10.1016/j.ejcts.2007.01.071
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Safety of the use of Tissucol^® Duo S in cardiovascular surgery: retrospective analysis of 2149 patients after coronary artery bypass grafting

^a Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl-Neuberg-Street 1, 30625 Hannover, Germany
^b Center of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Received 25 October 2006; received in revised form 21 January 2007; accepted 29 January 2007.

^_* Corresponding author. Tel.: +49 511 532 2153; fax: +49 511 532 5404. (Email: goerler.adelheid{at}mh-hannover.de).

Objective: Fibrin sealant is widely used in almost all fields of surgery and has proved to be an effective therapeutic tool in cardiothoracic surgery. Nevertheless, there have been concerns about early bypass graft occlusion associated with the use of fibrin glue. This analysis has been performed to assess the risks and benefits of Tissucol^® Duo S in coronary artery bypass grafting (CABG) surgery. Methods: Two thousand one hundred forty-nine patients were included in this retrospective study, 879 (40.9%) were intra-operatively treated with Tissucol^® Duo S fibrin glue, 1270 (59.1%) did not receive fibrin glue (control group). Patient characteristics were documented according to the EuroScore. Intra- and postoperative data were collected. Primary endpoint of this study was the 30-day all-cause mortality rate in the Tissucol^® Duo S treated group compared to the control group. Results: Mean age was 66.6 ± 9.4 years, 76.3% of the patients were male. There was an increased 30-day-mortality rate in the Tissucol^® Duo S group compared to the control group (8.5 vs 3.5%, p < 0.001). In order to determine if and to what extent the apparent fibrin effect might be due to confounding effects from covariates, an adjustment for potential confounding was done. However, multivariable adjustment did not reduce the risk of fibrin glue below an odds ratio of 2.2. Conclusion: Although the apparent increase in mortality risk associated with the use of fibrin glue could not be eliminated statistically, we consider Tissucol^® Duo S fibrin glue a safe and effective therapeutic tool in CABG surgery when it is applied correctly. Due to the retrospective character of this study some detailed information about the indication for the use of fibrin glue and its application is missing which may be important cofactors for mortality. For further clarification a prospective randomized study may be useful.

Key Words: Fibrin glue • Coronary artery bypass grafting • Myocardial infarction

This article has been cited by other articles:

				J. Terrovitis, R. Lautamaki, M. Bonios, J. Fox, J. M. Engles, J. Yu, M. K. Leppo, M. G. Pomper, R. L. Wahl, J. Seidel, et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1619 - 1626. [Abstract] [Full Text] [PDF]

				M. A. Erb, T. Claus, M. Hartrumpf, S. Bachmann, and J. M. Albes The use of Tachosil(R) surgical patch or fibrin glue in coronary artery surgery does not affect quality of anastomosis or provoke postoperative adhesions in pigs Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 703 - 707. [Abstract] [Full Text] [PDF]

				P. Akhyari, H. Kamiya, A. Haverich, M. Karck, and A. Lichtenberg Myocardial tissue engineering: the extracellular matrix. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 229 - 241. [Abstract] [Full Text] [PDF]

				R. F. Nistor Fibrin sealant in coronary artery bypass grafting surgery; reflection on risk and benefit Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 317 - 317. [Full Text] [PDF]

				P. Lamm and B. Reichart Reply to Nistor Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 318 - 318. [Full Text] [PDF]

				J. Cremer Fibrin glue in coronary surgery Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 559 - 559. [Full Text] [PDF]